1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Phase III studies for new uses of Celgene's Revlimid in multiple myeloma meet endpoints

 
• By Malini Guha

Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.

Two recent Phase III trials of Celgene's Revlimid (lenalidomide) have examined the potential for maintenance use of the drug in previously treated patients, while others have examined its use in newly diagnosed multiple myeloma (MM) patients, possibly paving the way for new uses for the drug.

Celgene told Scrip that while the independently-sponsored trials testing maintenance Revlimid met their primary progression-free survival (PFS) endpoints – such...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

More from Therapeutic Category

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

 
• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.